Incyte began its search in the mid-Atlantic area for a facility in September 2001, hoping to make the move the following spring. "Delaware's ability to provide readily available lab space and our significant research and development workforce played key roles in attracting Incyte to Delaware," Delaware Economic Development Office director John D. Wik tells GlobeSt.com. "Incyte's decision to locate in Delaware will greatly enhance our state's biotechnology resources. In addition, the research and development to be conducted at the company's new location will significantly boost Delaware's development as a global hub for biotechnology." The Stine-Haskell complex of buildings, which was dedicated half a century ago, sits on 530-acres.